Last 48 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.13 | 17.51 | 10.63 | 19.64 | 18.80 | 127.66 | 18.87 | 79.46 | 15.84 | 11.45 | 18.05 | 31.78 | 26.07 | 50.42 | 79.01 | 445.37 | 25.77 | 13.54 | — | 86.37 | 47.25 |
| — | -86.3% | -43.7% | -75.3% | +18.6% | +1014.7% | +4.5% | +150.1% | -39.2% | -77.3% | -77.2% | -92.9% | +1.2% | +272.4% | — | +415.7% | -45.5% | -80.5% | — | -18.0% | +36.7% | |
| P/S Ratio | 1.13 | 1.04 | 0.72 | 0.85 | 0.84 | 1.08 | 1.18 | 1.47 | 1.54 | 1.77 | 1.62 | 2.00 | 2.64 | 2.62 | 3.40 | 2.74 | 2.73 | 2.27 | 2.57 | 5.39 | 4.24 |
| — | -3.8% | -39.1% | -42.0% | -45.2% | -39.0% | -27.4% | -26.6% | -41.6% | -32.7% | -52.3% | -26.9% | -3.5% | +15.8% | +32.2% | -49.1% | -35.5% | -46.4% | -41.2% | +22.4% | +27.8% | |
| P/B Ratio | 1.55 | 1.31 | 0.95 | 1.06 | 1.22 | 1.45 | 1.61 | 1.92 | 2.21 | 2.40 | 2.45 | 2.93 | 4.14 | 4.01 | 5.54 | 4.31 | 3.68 | 3.48 | 4.24 | 6.61 | 5.91 |
| — | -9.3% | -41.3% | -44.7% | -44.9% | -39.6% | -34.0% | -34.3% | -46.5% | -40.2% | -55.8% | -32.0% | +12.5% | +15.3% | +30.7% | -34.9% | -37.8% | -37.4% | -29.3% | +17.1% | +25.1% | |
| P/FCF | 11.62 | 7.45 | 7.21 | 25.59 | 7.64 | 7.53 | 17.28 | 12.46 | 13.55 | 11.71 | 13.57 | 23.11 | 16.73 | 19.61 | 48.78 | — | — | 32.50 | 54.70 | — | 37.96 |
| — | -1.0% | -58.2% | +105.4% | -43.6% | -35.7% | +27.3% | -46.1% | -19.0% | -40.3% | -72.2% | — | — | -39.6% | -10.8% | — | — | -51.2% | +53.4% | — | -23.1% | |
| EV / EBITDA | 9.79 | 9.59 | 7.62 | 12.46 | 5.99 | 14.97 | 10.14 | 23.02 | 10.68 | 9.97 | 11.91 | 16.31 | 16.13 | 24.33 | 33.02 | 34.92 | 56.60 | 20.88 | 25.74 | 37.64 | 24.27 |
| — | -35.9% | -24.8% | -45.9% | -43.9% | +50.0% | -14.8% | +41.1% | -33.8% | -59.0% | -63.9% | -53.3% | -71.5% | +16.6% | +28.3% | -7.2% | +133.2% | -25.0% | -24.2% | +20.2% | +1.1% | |
| EV / EBIT | 16.56 | 14.54 | 11.36 | 18.77 | 14.02 | 47.88 | 16.33 | 42.89 | 14.34 | 11.95 | 16.42 | 24.71 | 21.91 | 34.47 | 48.63 | 84.25 | — | 36.05 | — | 65.87 | 35.66 |
| — | -69.6% | -30.4% | -56.2% | -2.2% | +300.8% | -0.5% | +73.6% | -34.6% | -65.3% | -66.2% | -70.7% | — | -4.4% | — | +27.9% | — | -24.5% | — | +10.1% | -14.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 56.4% | 57.5% | 57.9% | 57.1% | 46.7% | 52.6% | 52.6% | 57.3% | 56.5% | 55.3% | 55.1% | 55.7% | 55.2% | 53.7% | 52.6% | 52.6% | 55.1% | 54.8% | 56.1% | 56.9% |
| — | +20.8% | +9.2% | +10.1% | -0.4% | -17.5% | -4.9% | -4.6% | +2.9% | +2.4% | +3.0% | +4.8% | +6.0% | +0.1% | -1.9% | -6.3% | -7.6% | -3.6% | -1.2% | +1.7% | +6.1% | |
| Operating Margin | 10.3% | 11.1% | 10.6% | 8.0% | 17.9% | 5.7% | 12.2% | 3.6% | 15.2% | 20.7% | 14.2% | 11.2% | 15.3% | 9.9% | 8.6% | 4.3% | -0.4% | 8.8% | 8.8% | 9.3% | 13.6% |
| — | +93.2% | -12.9% | +123.1% | +18.0% | -72.4% | -14.3% | -67.9% | -1.1% | +108.6% | +64.3% | +160.9% | +3615.6% | +12.9% | -2.2% | -53.6% | -103.2% | -17.9% | -12.4% | +7.3% | +39.0% | |
| Net Margin | 3.4% | 5.9% | 6.7% | 4.4% | 4.5% | 0.8% | 6.2% | 1.9% | 9.8% | 15.5% | 9.0% | 6.3% | 10.1% | 5.2% | 4.3% | 0.6% | 10.6% | 16.8% | -60.7% | 6.2% | 8.9% |
| — | +598.6% | +7.6% | +130.8% | -54.1% | -94.5% | -30.8% | -70.1% | -3.5% | +197.5% | +108.8% | +925.3% | -4.6% | -69.0% | +107.1% | -90.0% | +18.8% | +179.3% | -1265.7% | +45.8% | -6.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.7% | 1.9% | 2.2% | 1.3% | 1.6% | 0.3% | 2.2% | 0.6% | 3.6% | 5.4% | 3.5% | 2.3% | 4.1% | 2.0% | 1.8% | 0.2% | 3.6% | 6.6% | -23.0% | 1.9% | 3.2% |
| — | +562.8% | +3.6% | +116.7% | -54.0% | -94.7% | -37.3% | -73.3% | -12.2% | +168.7% | +92.7% | +860.9% | +11.5% | -69.8% | +107.8% | -87.2% | +14.7% | +233.4% | -1372.8% | +38.3% | -8.5% | |
| ROA | 2.0% | 0.9% | 1.0% | 0.6% | 0.7% | 0.1% | 0.9% | 0.3% | 1.5% | 2.1% | 1.3% | 0.9% | 1.4% | 0.7% | 0.6% | 0.1% | 1.2% | 2.1% | -8.7% | 0.8% | 1.4% |
| — | +599.6% | +8.0% | +127.3% | -50.7% | -94.2% | -29.0% | -69.3% | +2.1% | +212.5% | +120.6% | +985.3% | +23.4% | -67.8% | +106.8% | -90.7% | -16.6% | +148.7% | -1251.6% | +49.6% | +0.5% | |
| ROIC | 5.8% | 1.5% | 1.5% | 1.0% | 2.7% | 0.8% | 1.7% | 0.5% | 2.1% | 2.7% | 1.9% | 1.5% | 2.1% | 1.3% | 1.1% | 0.5% | -0.0% | 1.1% | 1.2% | 1.1% | 1.9% |
| — | +91.9% | -12.7% | +121.9% | +28.4% | -70.6% | -12.7% | -68.0% | +1.3% | +112.0% | +69.6% | +173.2% | +4596.4% | +16.2% | -3.6% | -53.5% | -102.4% | -21.6% | -11.7% | +10.3% | +50.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.77 | 0.80 | 0.85 | 0.81 | 0.85 | 0.88 | 0.91 | 0.94 | 1.01 | 1.10 | 1.16 | 1.17 | 1.27 | 1.33 | 1.42 | 1.41 | 1.45 | 1.46 | 0.91 | 0.87 |
| — | -9.1% | -8.9% | -7.3% | -14.1% | -16.0% | -19.7% | -21.3% | -19.4% | -20.7% | -17.9% | -18.1% | -17.5% | -12.1% | -8.6% | +56.1% | +62.3% | +52.8% | +49.0% | -11.8% | -20.4% | |
| Debt / EBITDA | 3.88 | 14.48 | 14.27 | 22.48 | 9.74 | 22.46 | 14.51 | 30.01 | 12.85 | 11.95 | 14.87 | 18.68 | 14.28 | 23.59 | 25.78 | 34.77 | 63.38 | 24.76 | 26.76 | 18.22 | 12.52 |
| — | -35.5% | -1.6% | -25.1% | -24.2% | +87.9% | -2.4% | +60.7% | -10.0% | -49.3% | -42.3% | -46.3% | -77.5% | -4.7% | -3.7% | +90.8% | +406.3% | +51.9% | +39.0% | -6.2% | -31.1% | |
| Current Ratio | 2.14 | 1.49 | 1.48 | 2.29 | 2.14 | 2.10 | 2.23 | 2.26 | 2.30 | 2.27 | 2.34 | 2.18 | 1.98 | 1.66 | 1.74 | 1.90 | 1.96 | 2.75 | 2.87 | 2.60 | 2.34 |
| — | -29.4% | -33.5% | +1.5% | -7.2% | -7.3% | -4.7% | +3.4% | +16.1% | +36.6% | +34.4% | +14.7% | +1.1% | -39.6% | -39.3% | -26.9% | -16.2% | +13.7% | +28.5% | +11.7% | +6.8% | |
| Quick Ratio | 1.01 | 0.70 | 0.69 | 1.04 | 1.01 | 0.95 | 1.00 | 1.00 | 1.05 | 1.06 | 1.13 | 1.08 | 0.96 | 0.80 | 0.82 | 0.86 | 0.84 | 1.29 | 1.43 | 1.25 | 1.16 |
| — | -26.5% | -30.9% | +3.6% | -4.5% | -10.5% | -11.4% | -6.6% | +10.2% | +32.7% | +38.7% | +25.6% | +14.0% | -38.3% | -42.9% | -31.5% | -27.8% | +10.1% | +22.4% | +4.2% | -0.4% | |
| Interest Coverage | 3.29 | 3.34 | 4.98 | 3.60 | 4.97 | 1.56 | 4.82 | 1.93 | 5.93 | 7.10 | 4.91 | 3.65 | 5.28 | 3.02 | 2.74 | 1.24 | -0.12 | 2.84 | -14.77 | 4.49 | 4.92 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNMD stock.
CONMED Corporation's current P/E is 21.1x. The average P/E over the last 4 quarters is 16.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CONMED Corporation's current operating margin is 10.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CONMED Corporation's business trajectory between earnings reports.